Literature DB >> 3965821

Primary pulmonary hypertension: a histopathologic study of 80 cases.

J Bjornsson, W D Edwards.   

Abstract

Among 80 cases with a clinical diagnosis of primary (unexplained) pulmonary hypertension, 45 (56%) had thromboembolic disease and 22 (28%) had plexogenic arteriopathy; the remaining 13 (16%) had pulmonary veno-occlusive disease, primary medial hypertrophy, primary pulmonary arteritis, or changes consistent with pulmonary venous hypertension. The mean age was 16 years for primary pulmonary arteritis, 21 to 34 years for plexogenic pulmonary arteriopathy, primary medial hypertrophy, and pulmonary veno-occlusive disease, and 41 and 45 years for thromboembolic disease and pulmonary venous hypertension, respectively. In all forms except pulmonary veno-occlusive disease and apparent pulmonary venous hypertension, female patients were involved twice as often as male patients. With the exception of apparent pulmonary venous hypertension, patients with plexogenic pulmonary arteriopathy had the longest survival (63 months). Sudden death, however, occurred most frequently in patients with plexogenic disease (45%) and occurred 2.5 times as often in this group as in patients with thromboembolic disease. Among our 80 cases, the most frequent histopathologic lesions were medial hypertrophy, intimal proliferation and fibrosis, fibrinoid degeneration and necrosis, and thrombosis. Thrombi were commonly observed and may have developed in situ or by embolization; they were often rich in platelets when they occurred in small pulmonary vessels. These histologic features may form the morphologic substrate for elevated pulmonary vascular resistance, and their recognition may provide the rationale for possible intervention with pulmonary vasodilators, anticoagulants, or platelet inhibitors.

Entities:  

Mesh:

Year:  1985        PMID: 3965821     DOI: 10.1016/s0025-6196(12)65277-x

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  37 in total

Review 1.  Treatment of pulmonary hypertension secondary to connective tissue diseases.

Authors:  O Sanchez; M Humbert; O Sitbon; G Simonneau
Journal:  Thorax       Date:  1999-03       Impact factor: 9.139

2.  Modern age pathology of pulmonary arterial hypertension.

Authors:  Elvira Stacher; Brian B Graham; James M Hunt; Aneta Gandjeva; Steve D Groshong; Vallerie V McLaughlin; Marsha Jessup; William E Grizzle; Michaela A Aldred; Carlyne D Cool; Rubin M Tuder
Journal:  Am J Respir Crit Care Med       Date:  2012-06-07       Impact factor: 21.405

3.  Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension.

Authors:  K Okada; Y Tanaka; M Bernstein; W Zhang; G A Patterson; M D Botney
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

4.  The treatment of primary pulmonary hypertension.

Authors:  N G Uren; C M Oakley
Journal:  Br Heart J       Date:  1991-08

5.  Diagnostic dilemma in pulmonary arterial hypertension: idiopathic or chronic thromboembolic hypertension?

Authors:  U Canpolat; Ö Özeke; S Yılmaz; F N Başar; K Çağlı; Z Gölbaşı
Journal:  Herz       Date:  2013-12-04       Impact factor: 1.443

6.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

Authors:  R M Tuder; B Groves; D B Badesch; N F Voelkel
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

7.  Active collagen synthesis by pulmonary arteries in human primary pulmonary hypertension.

Authors:  M D Botney; M J Liptay; L R Kaiser; J D Cooper; W C Parks; R P Mecham
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

8.  Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?

Authors:  Muhammad Shahzeb Khan; Muhammad Shariq Usman; Tariq Jamal Siddiqi; Safi U Khan; M Hassan Murad; Farouk Mookadam; Vincent M Figueredo; Richard A Krasuski; Raymond L Benza; Jonathan D Rich
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-09

9.  Pulmonary hypertension: diagnosis and management.

Authors:  Michael D McGoon; Garvan C Kane
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

10.  Utility of d-dimer in the diagnosis of patients with chronic thromboembolic pulmonary hypertension.

Authors:  Vichaya Arunthari; Charles D Burger
Journal:  Open Respir Med J       Date:  2009-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.